Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day

PHILADELPHIA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
November 03, 2022 07:30 ET | Source: Passage Bio

Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
October 14, 2022 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
October 10, 2022 07:00 ET | Source: Passage Bio

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
September 26, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
August 19, 2022 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
August 11, 2022 07:00 ET | Source: Passage Bio

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
August 05, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference

PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
August 04, 2022 07:00 ET | Source: Passage Bio

Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights

Advanced Imagine-1 clinical trial for GM1 gangliosidosis to recruitment of final cohort, Cohort 4, in dose-ascending phase of study following recommendation by Independent Data Monitoring Committee...
July 28, 2022 07:30 ET | Source: Passage Bio

Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right